Webdisclosure.com

Search

ADC THERAPEUTICS SA EQS-News: ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Directive transparence : information réglementée

20/02/2019 07:00